Molecular subtypes of breast cancer, such as HER-2 (Human Epidermal Growth Factor Receptor 2)-positive breast cancer, have biological behaviors and prognostic characteristics that are significantly different from those of other subtypes and, therefore, require more refined treatment and management. Here, ERBB2 is linked to breast carcinoma.